CD134: Difference between revisions
imported>Rod57 m (→As a drug or drug target: [[) |
|||
| Line 13: | Line 13: | ||
An artificially created biologic [[fusion protein]], OX40-[[immunoglobulin]] (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Experiments in mice have demonstrated that OX40-Ig can reduce the symptoms associated with the cytokine storm (an immune overreaction) while allowing the immune system to fight off the virus successfully.{{Citation needed|date=April 2016}} | An artificially created biologic [[fusion protein]], OX40-[[immunoglobulin]] (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Experiments in mice have demonstrated that OX40-Ig can reduce the symptoms associated with the cytokine storm (an immune overreaction) while allowing the immune system to fight off the virus successfully.{{Citation needed|date=April 2016}} | ||
An anti-OX40 antibody [[GSK3174998]] has started clinical trials as a cancer treatment.<ref>[https://www.gsk.com/en-gb/media/press-releases/2015/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment/ GSK and Merck to study immunotherapy combination as potential cancer treatment. Nov 2015]</ref> | An anti-OX40 antibody [[GSK3174998]] has started clinical trials as a cancer treatment.<ref>[https://www.gsk.com/en-gb/media/press-releases/2015/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment/ GSK and Merck to study immunotherapy combination as potential cancer treatment. Nov 2015]</ref> Research in mice has included the combination of an [[agonistic]] OX40 antibody (clone OX86) injected directly into a tumor in combination with an unmethylated [[CpG oligonucleotide]], which as a [[TLR9]] ligand activates expression of OX40 so that it can be affected.<ref name="Sagiv-BarfiCzerwinski2018">{{cite journal|vauthors = Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, Levy R, |title = Eradication of spontaneous malignancy by local immunotherapy|journal = Science Translational Medicine|volume = 10|issue = 426|year = 2018|pages = eaan4488|issn = 1946-6234|doi = 10.1126/scitranslmed.aan4488}}</ref> | ||
== Interactions == | == Interactions == | ||
CD134 has been shown to [[Protein-protein interaction|interact]] with [[TRAF5]]<ref name=pmid9488716>{{cite journal | vauthors = Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T | title = Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation | journal = | CD134 has been shown to [[Protein-protein interaction|interact]] with [[TRAF5]]<ref name=pmid9488716>{{cite journal | vauthors = Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T | title = Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation | journal = The Journal of Biological Chemistry | volume = 273 | issue = 10 | pages = 5808–14 | date = March 1998 | pmid = 9488716 | doi = 10.1074/jbc.273.10.5808 }}</ref> and [[TRAF2]].<ref name=pmid9418902>{{cite journal | vauthors = Arch RH, Thompson CB | title = 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB | journal = Molecular and Cellular Biology | volume = 18 | issue = 1 | pages = 558–65 | date = January 1998 | pmid = 9418902 | pmc = 121523 }}</ref> | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
==External links== | == External links == | ||
* {{UCSC gene info|TNFRSF4}} | * {{UCSC gene info|TNFRSF4}} | ||
== Further reading == | == Further reading == | ||
{{refbegin|35em}} | {{refbegin|35em}} | ||
* {{cite journal | vauthors = So T, Salek-Ardakani S, Nakano H, Ware CF, Croft M | title = TNF receptor-associated factor 5 limits the induction of Th2 immune responses | journal = | * {{cite journal | vauthors = So T, Salek-Ardakani S, Nakano H, Ware CF, Croft M | title = TNF receptor-associated factor 5 limits the induction of Th2 immune responses | journal = Journal of Immunology | volume = 172 | issue = 7 | pages = 4292–7 | date = April 2004 | pmid = 15034043 | doi = 10.4049/jimmunol.172.7.4292 }} | ||
* {{cite journal | vauthors = Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M | title = The costimulation-regulated duration of PKB activation controls T cell longevity | journal = | * {{cite journal | vauthors = Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M | title = The costimulation-regulated duration of PKB activation controls T cell longevity | journal = Nature Immunology | volume = 5 | issue = 2 | pages = 150–8 | date = February 2004 | pmid = 14730361 | doi = 10.1038/ni1030 }} | ||
* {{cite journal | vauthors = Song J, So T, Cheng M, Tang X, Croft M | title = Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion | journal = Immunity | volume = 22 | issue = 5 | pages = 621–31 | | * {{cite journal | vauthors = Song J, So T, Cheng M, Tang X, Croft M | title = Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion | journal = Immunity | volume = 22 | issue = 5 | pages = 621–31 | date = May 2005 | pmid = 15894279 | doi = 10.1016/j.immuni.2005.03.012 }} | ||
* {{cite journal | vauthors = Croft M | title = Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? | journal = | * {{cite journal | vauthors = Croft M | title = Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? | journal = Nature Reviews. Immunology | volume = 3 | issue = 8 | pages = 609–20 | date = August 2003 | pmid = 12974476 | doi = 10.1038/nri1148 }} | ||
* {{cite journal | vauthors = Rogers PR, Song J, Gramaglia I, Killeen N, Croft M | title = OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells | journal = Immunity | volume = 15 | issue = 3 | pages = 445–55 | | * {{cite journal | vauthors = Rogers PR, Song J, Gramaglia I, Killeen N, Croft M | title = OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells | journal = Immunity | volume = 15 | issue = 3 | pages = 445–55 | date = September 2001 | pmid = 11567634 | doi = 10.1016/S1074-7613(01)00191-1 }} | ||
* {{cite journal | vauthors = Watts TH | title = TNF/TNFR family members in costimulation of T cell responses | journal = | * {{cite journal | vauthors = Watts TH | title = TNF/TNFR family members in costimulation of T cell responses | journal = Annual Review of Immunology | volume = 23 | issue = | pages = 23–68 | year = 2005 | pmid = 15771565 | doi = 10.1146/annurev.immunol.23.021704.115839 }} | ||
{{refend}} | {{refend}} | ||
Latest revision as of 14:15, 6 April 2018
| VALUE_ERROR (nil) | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Aliases | |||||||
| External IDs | GeneCards: [1] | ||||||
| Orthologs | |||||||
| Species | Human | Mouse | |||||
| Entrez |
|
| |||||
| Ensembl |
|
| |||||
| UniProt |
|
| |||||
| RefSeq (mRNA) |
|
| |||||
| RefSeq (protein) |
|
| |||||
| Location (UCSC) | n/a | n/a | |||||
| PubMed search | n/a | n/a | |||||
| Wikidata | |||||||
| |||||||
Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor, is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells, unlike CD28. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. Expression of OX40 is dependent on full activation of the T cell; without CD28, expression of OX40 is delayed and of fourfold lower levels.
Function
OX40 has no effect on the proliferative abilities of CD4+ cells for the first three days, however after this time proliferation begins to slow and cells die at a greater rate, due to an inability to maintain a high level of PKB activity and expression of Bcl-2, Bcl-XL and survivin. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response beyond the first few days and onwards to a memory response due to its ability to enhance survival. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions in vivo.
OX40 binds TRAF2, 3 and 5 as well as PI3K by an unknown mechanism. TRAF2 is required for survival via NF-κB and memory cell generation whereas TRAF5 seems to have a more negative or modulatory role, as knockouts have higher levels of cytokines and are more susceptible to Th2-mediated inflammation. TRAF3 may play a critical role in OX40-mediated signal transduction. CTLA-4 is down-regulated following OX40 engagement in vivo and the OX40-specific TRAF3 DN defect was partially overcome by CTLA-4 blockade in vivo. TRAF3 may be linked to OX40-mediated memory T cell expansion and survival, and point to the down-regulation of CTLA-4 as a possible control element to enhance early T cell expansion through OX40 signaling.
Clinical significance
OX40 has been implicated in the pathologic cytokine storm associated with certain viral infections, including the H5N1 bird flu.[citation needed]
As a drug or drug target
An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Experiments in mice have demonstrated that OX40-Ig can reduce the symptoms associated with the cytokine storm (an immune overreaction) while allowing the immune system to fight off the virus successfully.[citation needed]
An anti-OX40 antibody GSK3174998 has started clinical trials as a cancer treatment.[1] Research in mice has included the combination of an agonistic OX40 antibody (clone OX86) injected directly into a tumor in combination with an unmethylated CpG oligonucleotide, which as a TLR9 ligand activates expression of OX40 so that it can be affected.[2]
Interactions
CD134 has been shown to interact with TRAF5[3] and TRAF2.[4]
References
- ↑ GSK and Merck to study immunotherapy combination as potential cancer treatment. Nov 2015
- ↑ Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, Levy R (2018). "Eradication of spontaneous malignancy by local immunotherapy". Science Translational Medicine. 10 (426): eaan4488. doi:10.1126/scitranslmed.aan4488. ISSN 1946-6234.
- ↑ Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T (March 1998). "Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation". The Journal of Biological Chemistry. 273 (10): 5808–14. doi:10.1074/jbc.273.10.5808. PMID 9488716.
- ↑ Arch RH, Thompson CB (January 1998). "4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB". Molecular and Cellular Biology. 18 (1): 558–65. PMC 121523. PMID 9418902.
External links
- Human TNFRSF4 genome location and TNFRSF4 gene details page in the UCSC Genome Browser.
Further reading
- So T, Salek-Ardakani S, Nakano H, Ware CF, Croft M (April 2004). "TNF receptor-associated factor 5 limits the induction of Th2 immune responses". Journal of Immunology. 172 (7): 4292–7. doi:10.4049/jimmunol.172.7.4292. PMID 15034043.
- Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M (February 2004). "The costimulation-regulated duration of PKB activation controls T cell longevity". Nature Immunology. 5 (2): 150–8. doi:10.1038/ni1030. PMID 14730361.
- Song J, So T, Cheng M, Tang X, Croft M (May 2005). "Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion". Immunity. 22 (5): 621–31. doi:10.1016/j.immuni.2005.03.012. PMID 15894279.
- Croft M (August 2003). "Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?". Nature Reviews. Immunology. 3 (8): 609–20. doi:10.1038/nri1148. PMID 12974476.
- Rogers PR, Song J, Gramaglia I, Killeen N, Croft M (September 2001). "OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells". Immunity. 15 (3): 445–55. doi:10.1016/S1074-7613(01)00191-1. PMID 11567634.
- Watts TH (2005). "TNF/TNFR family members in costimulation of T cell responses". Annual Review of Immunology. 23: 23–68. doi:10.1146/annurev.immunol.23.021704.115839. PMID 15771565.